ADC

192개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved192 programs
ADCStandard DatabasestalePfizerPhase 3

Mylotarg (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (Mylotarg))

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#antibody-drug-conjugate#Pfizer
Trials 30Status Active
ADCStandard DatabasestaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab, trastuzumab-emtansine)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 30Status Active
ADCStandard DatabasestaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
ADCLimited DatastaleLepu Medical Technology (Beijin…Phase 3

Becotatug Vedotin (Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Adenoid Cystic Carcinoma

#AdenoidCysticCarcinoma#ADC#Phase3#antibody-drug-conjugate#NasopharyngealCancinomaNPC+1
Trials 28Status Recruiting
ADCStandard DatabasestaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Drug: Disitamab Vedotin)

Upper Urinary Tract Urothelial Carcinoma · Upper Urinary Tract Urothelial Carcinoma

#UpperUrinaryTractUrothelialCarci#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 26Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 25Status Recruiting
ADCStandard DatabasestaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
ADCStandard DatabasestaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
ADCStandard DatabasestaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#antibody-drug-conjugate#Byondis
Trials 23Status Active
ADCStandard DatabasestaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Recurrent or Metastatic Solid Tumors · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+2
Trials 18Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#antibody-drug-conjugate#NeoadjuvantTherapy+1
Trials 17Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Toripalimab)

Paget Disease, Extramammary; Scrotum Disease · Paget Disease, Extramammary

#PagetDiseaseExtramammary#ADC#Phase2#antibody-drug-conjugate#PagetDisease+3
Trials 17Status Recruiting
ADCStandard DatabasestaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#HER2+BreastCancer+1
Trials 17Status Recruiting
ADCLimited DatastaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, tislelizumab+disitamab-vedotin)

Neoadjuvant Immunotherapy · Neoadjuvant Immunotherapy

#NeoadjuvantImmunotherapy#ADC#Phase2#antibody-drug-conjugate#BeiGene
Trials 17Status Recruiting
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 13Status Recruiting

4 / 10 pages

← PreviousNext →